文献速递生殖医学

促性腺激素与克罗米芬促排卵在宫腔内人工授精项目中的成本效果

Cost-effectiveness of ovarian stimulation with gonadotrophin and clomiphene citrate in an intrauterine insemination programme for subfertile couples.
PubMed 文献 · Reprod Biomed Online · 2017-12-27

本研究基于一项纳入620个宫腔内人工授精周期的随机试验,比较低剂量人绝经期促性腺激素(HMG,每日皮下注射37.5-75 IU)与口服克罗米芬(50 mg/日,第3-7天)的成本效果。HMG组每例总成本€764,克罗米芬组€558,增量成本€206;HMG组临床妊娠率亦高出5.7个百分点,增量成本效果比(ICER)为每额外获得一例临床妊娠€3615。平均而言,HMG较克罗米芬更具成本效果。

要点

  • HMG组每例总成本€764,较克罗米芬组€558增加€206。
  • HMG组临床妊娠率较克罗米芬组高5.7个百分点。
  • HMG对比克罗米芬的ICER为每额外临床妊娠€3615。

核心结论

  • 平均而言,HMG较克罗米芬更具成本效果。

研究设计与样本

  • 基于一项随机试验的成本效果分析,共纳入620个宫腔内人工授精周期。

主要发现

  • HMG组每例总成本€764,克罗米芬组€558,HMG增量成本为每治疗周期€206。
  • HMG组临床妊娠率较克罗米芬组高5.7个百分点。
  • HMG对比克罗米芬的ICER为每额外临床妊娠€3615。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ovarian stimulation with low-dose human menopausal gonadotrophin (HMG) is superior to clomiphene citrate in intrauterine insemination (IUI) cycles with respect to clinical pregnancy rate, but it is unclear whether HMG is also the more cost-effective option. The aim of this study was to compare the cost-effectiveness of ovarian stimulation with low-dose subcutaneously administred HMG (37.5-75 IU per day) to orally administred clomiphene citrate (50 mg/day from day 3-7) in an IUI programme for subfertile couples. A cost-effectiveness analysis was conducted using the results of a randomized trial, including 620 IUI cycles. The primary outcome was the incremental cost-effectiveness ratio (ICER) of using HMG versus clomiphene citrate. Results are presented from the healthcare payer perspective. The total cost per patient associated with one IUI treatment with HMG is €764, whereas it is €558 if clomiphene citrate is used, resulting in an incremental cost of €206 for HMG per treatment. The incremental clinical pregnancy rate of using HMG instead of clomiphene citrate, however, is also 5.7 percentage points higher, resulting in an ICER of HMG versus clomiphene citrate of €3615 per additional clinical pregnancy achieved. On average, HMG was found to be more cost-effective than clomiphene citrate.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Peeraer K, Luyten J, Tomassetti C, et al. Cost-effectiveness of ovarian stimulation with gonadotrophin and clomiphene citrate in an intrauterine insemination programme for subfertile couples. Reprod Biomed Online. 2017. PMID: 29395750. doi:10.1016/j.rbmo.2017.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。